Dietary iron concentration may influence aging process by altering oxidative stress in tissues of adult rats

Iron is an essential element. However, in its free form, iron participates in redox-reactions, leading to the production of free radicals that increase oxidative stress and the risk of damaging processes. Living organisms have an efficient mechanism that regulates iron absorption according to their iron content to protect against oxidative damage. The effects of restricted and enriched-iron diets on oxidative stress and aging biomarkers were investigated. Adult Wistar rats were fed diets containing 10, 35 or 350 mg/kg iron (adult restricted-iron, adult control-iron and adult enriched-iron groups, respectively) for 78 days. Rats aged two months were included as a young control group. Young control group showed higher hemoglobin and hematocrit values, lower levels of iron and lower levels of MDA or carbonyl in the major studied tissues than the adult control group. Restricted-iron diet reduced iron concentrations in skeletal muscle and oxidative damage in the majority of tissues and also increased weight loss. Enriched-iron diet increased hematocrit values, serum iron, gammaglutamyl transferase, iron concentrations and oxidative stress in the majority of tissues. As expected, young rats showed higher mRNA levels of heart and hepatic L-Ferritin (Ftl) and kidneys SMP30 as well as lower mRNA levels of hepatic Hamp and interleukin-1 beta (Il1b) and also lower levels of liver protein ferritin. Restricted-iron adult rats showed an increase in heart Ftl mRNA and the enriched-iron adult rats showed an increase in liver nuclear factor erythroid derived 2 like 2 (Nfe2l2) and Il1b mRNAs and in gut divalent metal transporter-1 mRNA (Slc11a2) relative to the control adult group. These results suggest that iron supplementation in adult rats may accelerate aging process by increasing oxidative stress while iron restriction may retards it. However, iron restriction may also impair other physiological processes that are not associated with aging

The binding of calcium to troponin C analyzed by flow dialysis, and fluorescence spectroscopy

A troponina C é o componente do complexo heterotrimérico troponina ao qual o Ca2+ se associa. Essa associação torna a contração muscular um processo regulado por Ca2+. Pearlstone et al. (Biochemistry 31, 6545, (1992)) utilizaram o cDNA da troponina C de músculo esquelético de galinha (sTnC) para construir um mutante onde a fenilalanina da posição 29 foi substituída por triptofano (mutante F29W). Esse mutante permitiu que a ligação de Ca2+ aos sítios regulatórios amino terminais fosse acompanhada através de técnicas fluorescentes. Entretanto, algumas propriedades da sTnC foram alteradas pela mutação (Li et al. (1995) Biochemistry 34, 8330). No presente estudo, ensaios de ligação direta de Ca2+ bem como titulações de Ca2+ seguidas por fluorescência foram usadas para melhor se entenderem os efeitos da mutação Phe→Trp na posição 29 bem como a influência de certos aminoácidos componentes do sítio de ligação de Ca2+ nas propriedades do domínio regulatório. Dois novos mutantes foram construídos nos quais os análogos do triptofano 5-hidroxitriptofano ou 7 -azatriptofano foram introduzidos na posição 29 (resultando nos mutantes F29HW e F29ZW, respectivamente). Os dados mostraram que, quando comparada com a sTnC, a afinidade por Ca2+ dos sítios amino terminais foi elevada na F29W em aproximadamente seis vezes, três vezes na F29ZW e levemente diminuída na F29HW . A curva de fluorescência associada à ligação de Ca2+ à F29ZW mostrou-se bimodal, com cada fase podendo ser relacionada à ligação de Ca2+ a cada um dos sítios regulatórios. Esta é a primeira descrição através de técnicas de fluorescência da ligação sequencial de Ca2+ aos sítios amino terminais. Para investigar a influência de cada um dos sítios amino terminais nas propriedades de ligação ao Ca2+ ou propriedades fluorescentes da sTnC, F29W, F29HW e F29ZW , construímos mutantes duplos e triplos através da substituição do aspartato da posição 30 ou 66 (ou ambos) por alanina. Essas mutações afetam respectivamente a capacidade de ligação ao Ca2+ dos sítios I e II. Os dados mostraram que: 1) nas concentrações de Ca2+ analisadas, a mutação Asp→Ala na posição 30 impede somente a ligação de Ca2+ ao sítio I, enquanto a mutação Asp → Ala na posição 66 impede a ligação de Ca2+ aos sítios I e II, e 2) a mutação Asp → Ala na posição 30 torna silenciosa a substituição da fenilalanina da posição 29 por Trp, 5-hidroxitriptofano ou 7-azatriptofano. Concluímos que o sítio I é essencialmente inativo sem a ligação prévia de Ca2+ ao sítio II e que a posição 29 influencia a afinidade ao Ca2+ do sítio I \"ajustado\".Troponin C is the Ca2+ binding component of heterotrimeric troponin. It makes skeletal muscle contraction a Ca2+ regulated process. We have previously used the cDNA of chicken skeletal TnC (sTnC) to construct a mutant where phenylalanine at position 29 was replaced by tryptophan (F29W mutant) [Pearlstone et al. (1992) Biochemistry 31, 6545]. This mutant allowed calcium binding to the regulatory amino terminal sites to be followed through fluorescence techniques, but altered some properties of sTnC [Li et al. (1995) Biochemistry 34, 8330]. In the present study, direct calcium binding assays and fluorescence followed calcium titrations were used to better understand the effects of the Phe→Trp mutation at position 29 as well as the influence of each amino site on the calcium binding properties of the regulatory domain. Two new mutants were constructed in which the tryptophan analogs 5-hydroxytryptophan or 7-azatryptophan were introduced at position 29 (resulting in F29HW and F29ZW mutants, respectively). The data showed that when compared to sTnC, the Ca2+ affinity of amino sites was increased sixfold in F29W, nearly threefold in F29ZW and slightly decreased in F29HW. The F29ZW fluorescence followed Ca2+ titration displayed a bimodal curve that could be related to Ca2+ binding to each of the amino sites. This is the first report of fluorescence detection of the sequential Ca2+ binding to the regulatory sites. To investigate the influence of each amino site in the calcium binding or fluorescence properties of sTnC, F29W, F29HW and F29ZW, we have constructed double and triple mutants by replacing aspartate at position 30 or 66 (or both) by alanine. These mutations affect respectively the binding capacity of sites I and II. The data showed that: 1) in the calcium concentration range analyzed, the Asp→Ala mutation at position 30 impairs calcium binding to site I on1y, while Asp→Ala mutation at position 66 impairs calcium binding to both sites I and II, and 2) the Asp→Ala mutation at position 30 makes silent the replacement of Phe at position 29 by Trp, 5-hydroxytryptophan or 7-azatryptophan. We conclude that site I is essentially defunct without previous binding to site II and that position 29 influences the affinity of this adjusted site I

The binding of calcium to troponin C analyzed by flow dialysis, and fluorescence spectroscopy

A troponina C é o componente do complexo heterotrimérico troponina ao qual o Ca2+ se associa. Essa associação torna a contração muscular um processo regulado por Ca2+. Pearlstone et al. (Biochemistry 31, 6545, (1992)) utilizaram o cDNA da troponina C de músculo esquelético de galinha (sTnC) para construir um mutante onde a fenilalanina da posição 29 foi substituída por triptofano (mutante F29W). Esse mutante permitiu que a ligação de Ca2+ aos sítios regulatórios amino terminais fosse acompanhada através de técnicas fluorescentes. Entretanto, algumas propriedades da sTnC foram alteradas pela mutação (Li et al. (1995) Biochemistry 34, 8330). No presente estudo, ensaios de ligação direta de Ca2+ bem como titulações de Ca2+ seguidas por fluorescência foram usadas para melhor se entenderem os efeitos da mutação Phe→Trp na posição 29 bem como a influência de certos aminoácidos componentes do sítio de ligação de Ca2+ nas propriedades do domínio regulatório. Dois novos mutantes foram construídos nos quais os análogos do triptofano 5-hidroxitriptofano ou 7 -azatriptofano foram introduzidos na posição 29 (resultando nos mutantes F29HW e F29ZW, respectivamente). Os dados mostraram que, quando comparada com a sTnC, a afinidade por Ca2+ dos sítios amino terminais foi elevada na F29W em aproximadamente seis vezes, três vezes na F29ZW e levemente diminuída na F29HW . A curva de fluorescência associada à ligação de Ca2+ à F29ZW mostrou-se bimodal, com cada fase podendo ser relacionada à ligação de Ca2+ a cada um dos sítios regulatórios. Esta é a primeira descrição através de técnicas de fluorescência da ligação sequencial de Ca2+ aos sítios amino terminais. Para investigar a influência de cada um dos sítios amino terminais nas propriedades de ligação ao Ca2+ ou propriedades fluorescentes da sTnC, F29W, F29HW e F29ZW , construímos mutantes duplos e triplos através da substituição do aspartato da posição 30 ou 66 (ou ambos) por alanina. Essas mutações afetam respectivamente a capacidade de ligação ao Ca2+ dos sítios I e II. Os dados mostraram que: 1) nas concentrações de Ca2+ analisadas, a mutação Asp→Ala na posição 30 impede somente a ligação de Ca2+ ao sítio I, enquanto a mutação Asp → Ala na posição 66 impede a ligação de Ca2+ aos sítios I e II, e 2) a mutação Asp → Ala na posição 30 torna silenciosa a substituição da fenilalanina da posição 29 por Trp, 5-hidroxitriptofano ou 7-azatriptofano. Concluímos que o sítio I é essencialmente inativo sem a ligação prévia de Ca2+ ao sítio II e que a posição 29 influencia a afinidade ao Ca2+ do sítio I \"ajustado\".Troponin C is the Ca2+ binding component of heterotrimeric troponin. It makes skeletal muscle contraction a Ca2+ regulated process. We have previously used the cDNA of chicken skeletal TnC (sTnC) to construct a mutant where phenylalanine at position 29 was replaced by tryptophan (F29W mutant) [Pearlstone et al. (1992) Biochemistry 31, 6545]. This mutant allowed calcium binding to the regulatory amino terminal sites to be followed through fluorescence techniques, but altered some properties of sTnC [Li et al. (1995) Biochemistry 34, 8330]. In the present study, direct calcium binding assays and fluorescence followed calcium titrations were used to better understand the effects of the Phe→Trp mutation at position 29 as well as the influence of each amino site on the calcium binding properties of the regulatory domain. Two new mutants were constructed in which the tryptophan analogs 5-hydroxytryptophan or 7-azatryptophan were introduced at position 29 (resulting in F29HW and F29ZW mutants, respectively). The data showed that when compared to sTnC, the Ca2+ affinity of amino sites was increased sixfold in F29W, nearly threefold in F29ZW and slightly decreased in F29HW. The F29ZW fluorescence followed Ca2+ titration displayed a bimodal curve that could be related to Ca2+ binding to each of the amino sites. This is the first report of fluorescence detection of the sequential Ca2+ binding to the regulatory sites. To investigate the influence of each amino site in the calcium binding or fluorescence properties of sTnC, F29W, F29HW and F29ZW, we have constructed double and triple mutants by replacing aspartate at position 30 or 66 (or both) by alanine. These mutations affect respectively the binding capacity of sites I and II. The data showed that: 1) in the calcium concentration range analyzed, the Asp→Ala mutation at position 30 impairs calcium binding to site I on1y, while Asp→Ala mutation at position 66 impairs calcium binding to both sites I and II, and 2) the Asp→Ala mutation at position 30 makes silent the replacement of Phe at position 29 by Trp, 5-hydroxytryptophan or 7-azatryptophan. We conclude that site I is essentially defunct without previous binding to site II and that position 29 influences the affinity of this adjusted site I

Quantification of SMP30, Ferritin (Ftl), Hepcidin (Hamp), Creb3l3, Nuclear factor erythroid derived 2 like 2 (Nfe2l2) and interleukin-1 beta (Il1b) mRNA from the livers of adult rats treated with control and restricted-iron (ARI) or enriched-iron (AEI) diets and of young rats (Gene/b-actin mRNA ratio - fold change).

<p>Average and standard deviation: n = 7 (CT); n = 5 (ARI); n = 8 (AEI); n = 6 (young). Difference between control group and test groups: *p≤0.05; **p≤0.01; ***p≤0.001 (Student's t-test). RT-PCR analyses were normalized against the mRNA expression of the housekeeping gene (β-actin gene) in the same tissue sample and then expressed as the “test/control” ratios.</p

Specific activity of catalase (A), GR (B), GPX (C), GST (D) and Nox (E) from tissue homogenates of adult rats treated with control and restricted-iron (ARI) or enriched-iron (AEI) diets and of young rats (U/mg of protein).

<p>Average and standard deviation: n = 7 (CT); n = 5 (ARI); n = 8 (AEI); n = 6 (young). Difference between control group and test groups:*p≤0.05; **p≤0.01; ***p≤0.001 (Student's t-test). GR, glutathione reductase; GPX, glutathione peroxidase; GST, glutathione-S-transferase; Nox, Nicotinamide adenine dinucleotide phosphate oxidase.</p

Hematological parameters of adult rats treated with control and restricted-iron (ARI) or enriched-iron (AEI) diets and of young rats.

<p>Average and standard deviation: n = 7 (CT); n = 5 (ARI); n = 8 (AEI); n = 6 (young). Difference between the control group and test groups:</p>*<p>p≤0.05;</p>**<p>p≤0.01;</p>***<p>p≤0.001 (Student's t-test).</p

Food intake, iron intake, initial and final body weight of adult rats treated with control and restricted-iron (ARI) or enriched-iron (AEI) diets during a 78-day treatment period.

<p>Average and standard deviation: n = 7 (CT); n = 5 (ARI); n = 8 (AEI). Difference between the control group and test groups:</p>*<p>p≤0.05;</p>**<p>p≤0.01;</p>***<p>p≤0.001 (Student's t-test).</p

Concentration of iron in the tissues of adult rats treated with control and restricted-iron (ARI) or enriched-iron (AEI) diets and of young rats (µg of iron/g tissue).

<p>Average and standard deviation: n = 7 (CT); n = 5 (ARI); n = 8 (AEI); n = 6 (young). Difference between control group and test groups: *p≤0.05; **p≤0.01; ***p≤0.001 (Student's t-test).</p

Malondialdehyde (MDA) (A) and protein carbonyl concentration (B) in liver, spleen, heart, kidney, gut and skeletal muscle homogenates of young rats and adult rats treated with control and restricted-iron (ARI) or enriched-iron (AEI) diets (nmols MDA/mg of protein and nmols carbonyl/mg of protein).

<p>Average and standard deviation: n = 7 (CT); n = 5 (ARI); n = 8 (AEI); n = 6 (young). Difference between control group and test groups:*p≤0.05; **p≤0.01; ***p≤0.001 (Student's t-test).</p